- Home » News and Events

NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity at Winchester, Kentucky
May 19, 2022
Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.
Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
May 16, 2022
The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.
Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility
Apr 28, 2022
Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.
Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech
Apr 25, 2022
Catalent today announced that it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for $44.5 million.
Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility
Apr 21, 2022
The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.
Catalent Adds New High-Throughput Encapsulation Manufacturing Suites at Kansas City, Missouri, Facility
Apr 14, 2022
Catalent today announced that it has completed the installation and commissioning of four new high throughput ‘high-bay’ CGMP manufacturing suites at its facility in Kansas City, Missouri, to increase its capacity and capabilities for producing oral solid dose forms.
Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe
Apr 5, 2022
Catalent today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
Catalent Appoints Frederic Cedrone as Vice President, Corporate Innovation
Mar 17, 2022
Dr. Cedrone will collaborate closely with Catalent’s scientific teams and external partners to leverage innovative technologies in the development of emerging therapeutic modalities.
Catalent Biologics Completes $30 Million Project for Biopharmaceutical Development and Drug Product Manufacturing in Limoges, France
Mar 16, 2022
Catalent today announced the completion of a $30 million project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
Key Considerations for Selection and Encapsulation of Capsules for Dry Powder Inhalation
Date: June 8, 2022
BIO International Convention 2022
Date: June 13-16, 2022
ISSCR Annual Meeting 2022
Date: June 15-18, 2022
BSMA Annual Conference 2022
Date: June 22-23, 2022
Unraveling the Complexities in Nasal Vaccine Development, Manufacturing and Device Selection
Date: June 29, 2022
CASSS Bioassays 2022
Date: July 19-21, 2022
DIA China 2022
Date: July 21-24, 2022
Inhalation & Respiratory Drug Delivery USA Congress
Date: October 11-12, 2022